Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Final Rx Labeling Rule Should Not Preempt State Product Liability Laws, States Say

This article was originally published in The Pink Sheet Daily

Executive Summary

National Conference of State Legislatures alleges that FDA’s final labeling rule will include language limiting state product liability laws.

You may also be interested in...

FDA Chief Counsel Says Generic Firms Make Strong Case For Preemption

Generic product liability suits are on the rise, which could result in more generic drug makers arguing for federal preemption, Bradshaw says.

Former FDA Lawyers: Reinstate $500,000 In Approps To Chief Counsel's Office

Five former top agency lawyers say filing of amicus briefs in product liability cases is a longstanding practice that predates current Chief Counsel Dan Troy. Rep. Hinchey's justification for shifting $500,000 out of the chief counsel's budget "cannot be supported," the lawyers tell Congress.

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts